Ionis Pharmaceuticals IONS Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Collaborative Agreement Revenue | $120.66M+168% | $52.4M-45.9% | $31.44M-30.0% | $336.92M+138% | $45.03M-8.7% | |
| Commercial | $107.81M+41.5% | $141.33M+64.9% | $115.6M+52.6% | $102.76M+42.6% | $76.17M+27.8% | |
| DAWNZERA Sales | $15.86M— | —— | —— | —— | $0— | |
| Other Commercial | $6.53M+14.3% | $7.65M-9.5% | $8.11M-9.1% | $13.53M+65.2% | $5.72M-44.0% | |
| Other Royalties | $3.9M-42.5% | $5.7M+55.8% | $6.48M+53.2% | $5.2M+56.6% | $6.78M-30.8% | |
| Research And Development Revenue | $138.28M+149% | $62.01M-56.0% | $41.12M-29.2% | $349.29M+128% | $55.44M-7.4% | |
| Royalty | $58.32M-9.1% | $75.72M-2.0% | $75.69M+13.3% | $69.95M+9.6% | $64.17M+29.9% | |
| Spinraza Royalties | $43.71M-9.0% | $54.04M-15.1% | $55.9M-2.3% | $54.34M-4.2% | $48.01M+24.8% | |
| Tryngolza | $27.1M+331% | —— | $31.79M— | $19.27M— | $6.29M— | |
| Wainua Joint Development Revenue | $17.62M+69.2% | $9.61M-78.1% | $9.69M-26.6% | $12.37M+5.8% | $10.41M-1.4% | |
| Wainus Royalties | $10.71M+14.3% | $15.98M+61.0% | $13.32M+148% | $10.42M+175% | $9.37M+733% | |
| Percentage Of Royalty Payments Paid On Annual Sales Of Medicine by Product | ||||||
| Pelacarsen | 25%0.0pp | —— | 25%0.0pp | 25%0.0pp | 25%0.0pp | |
| Spinraza | 45%0.0pp | —— | 45%0.0pp | 45%0.0pp | 45%0.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Ionis Pharmaceuticals break its business down?
- Ionis Pharmaceuticals (IONS) reports revenue by product across 11 parts — Collaborative Agreement Revenue, Commercial, DAWNZERA Sales, Other Commercial and Other Royalties. Each is extracted from the segment footnotes and tracked over time.
- Where does Ionis Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Ionis Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
